Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: A, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 47, which is 20 points higher than the healthcare sector average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock lose -11.29% over the past year, overperforming other healthcare stocks by 34 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 73.61% from Bioventus's current stock price of $8.64.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #2 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: A, Momentum: B, Sentiment: B, Safety: C, Financials: C, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 35, which is 8 points higher than the healthcare sector average of 27. It passed 11 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 31.3% over the past year, overperforming other healthcare stocks by 77 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $15.00, an upside of 26.8% from Amneal Pharmaceuticals's current stock price of $11.83.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aveanna Healthcare Holdings (NASDAQ:AVAH) is the #3 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aveanna Healthcare Holdings (NASDAQ:AVAH) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Aveanna Healthcare Holdings (NASDAQ:AVAH) has a Due Diligence Score of 32, which is 5 points higher than the healthcare sector average of 27. It passed 11 out of 33 due diligence checks and has average fundamentals. Aveanna Healthcare Holdings has seen its stock return 19.41% over the past year, overperforming other healthcare stocks by 65 percentage points.

Aveanna Healthcare Holdings has an average 1 year price target of $10.58, an upside of 62.32% from Aveanna Healthcare Holdings's current stock price of $6.52.

Aveanna Healthcare Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Aveanna Healthcare Holdings, 33.33% have issued a Strong Buy rating, 16.67% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 71 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Kamada (NASDAQ:KMDA) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 6.84%.

Kamada's dividend payout ratio of 57.1% indicates that its dividend yield is sustainable for the long-term.

Novabay Pharmaceuticals (NYSEMKT:NBY) has an annual dividend yield of 344.83%, which is 338 percentage points higher than the healthcare sector average of 6.84%.

Novabay Pharmaceuticals's dividend payout ratio of -105.3% indicates that its high dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 23.25%, which is 16 percentage points higher than the healthcare sector average of 6.84%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -1.33% in the last day, and down -1.91% over the last week. Milestone Pharmaceuticals was the among the top losers in the healthcare sector, dropping -20% yesterday.

Milestone Pharmaceuticals shares are trading lower. The company reported its Q4 financial results.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 86, which is 69 points higher than the healthcare sector average of 17. It passed 6 out of 7 valuation due diligence checks.

Embecta's stock has dropped -32.8% in the past year. It has overperformed other stocks in the healthcare sector by 13 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 98.69% in the past year. It has overperformed other stocks in the healthcare sector by 144 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -20.57% in the past year. It has overperformed other stocks in the healthcare sector by 25 percentage points.

58.57% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 48.08% over the next year.

5.24% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.55% of healthcare stocks are rated B (Buy), 50.55% are rated C (Hold), 23.75% are rated D (Sell), and 7.92% are rated F (Strong Sell).